HepaRegenix key facts
as of Oct 2026- Developer of novel therapies designed to treat acute and chronic liver diseases.
- HepaRegenix is valued at approximately $43.2M as of Oct 2026 (last reported valuation).
- It has raised $45.3M; the latest was Later Stage VC ($23.6M) in Apr 2025.
- Notable investors include High-Tech Gründerfonds, Novo Holdings, Boehringer Ingelheim Venture Fund, Wellington Partners, Ascenion — 7 tracked in total.
- Status: Privately Held (backing).
HepaRegenix's last reported valuation, Jan 2020. Nothing priced has surfaced since.
- ·Watch HepaRegenix: the Monday email on marks, rounds and moves
HepaRegenix funding rounds
No funding rounds for HepaRegenix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
HepaRegenix valuation
HepaRegenix's last reported valuation was $43.2 million in Jan 2020. No priced round, secondary trade or fund mark has surfaced since.
HepaRegenix investors
7 investors are on record for HepaRegenix, including High-Tech Gründerfonds, Novo Holdings, Boehringer Ingelheim Venture Fund and Wellington Partners.
About HepaRegenix
Developer of novel therapies designed to treat acute and chronic liver diseases. The company offers small-molecule drug development based on targeting regulatory pathways involved in liver regeneration and cellular repair to create therapies for treating acute and chronic liver diseases, enabling patients with liver conditions and healthcare providers to improve recovery of liver function and support treatment outcomes.
- Sector
- Healthcare
- HQ
- Tubingen, Germany
- Founded
- 2015
- Employees
- 10
- Website
- heparegenix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.